SENORESPharmaceuticals
Senores Pharmaceuticals Ltd — Profit & Loss Statement
₹759.60
+0.92%
Senores Pharmaceuticals Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | 0.00 | 0.00 | -9657.00 | 0.00 |
| Tax Rate For Calcs | 0.17 | 0.30 | 0.32 | 0.13 |
| Normalized EBITDA | 108.96 Cr | 44.41 Cr | 16.06 Cr | 2.36 Cr |
| Net Income From Continuing Operation Net Minority Interest | 58.56 Cr | 31.45 Cr | 8.43 Cr | 0.99 Cr |
| Reconciled Depreciation | 16.84 Cr | 10.02 Cr | 1.78 Cr | 0.70 Cr |
| Reconciled Cost Of Revenue | 180.70 Cr | 106.14 Cr | 12.77 Cr | 8.03 Cr |
| EBITDA | 108.96 Cr | 44.41 Cr | 16.05 Cr | 2.36 Cr |
| EBIT | 92.12 Cr | 34.39 Cr | 14.27 Cr | 1.65 Cr |
| Net Interest Income | -21.55 Cr | -9.45 Cr | -2.10 Cr | -0.37 Cr |
| Interest Expense | 21.55 Cr | 9.45 Cr | 1.84 Cr | 0.51 Cr |
| Normalized Income | 58.56 Cr | 31.45 Cr | 8.44 Cr | 0.99 Cr |
| Net Income From Continuing And Discontinued Operation | 58.56 Cr | 31.45 Cr | 8.43 Cr | 0.99 Cr |
| Total Expenses | 325.39 Cr | 182.97 Cr | 24.43 Cr | 12.82 Cr |
| Diluted Average Shares | 3.63 Cr | 4.61 Cr | 4.61 Cr | 4.61 Cr |
| Basic Average Shares | 3.63 Cr | 4.61 Cr | 4.61 Cr | 4.61 Cr |
| Diluted EPS | 16.12 | 6.83 | 1.83 | 0.22 |
| Basic EPS | 16.12 | 6.83 | 1.83 | 0.22 |
| Diluted NI Availto Com Stockholders | 58.56 Cr | 31.45 Cr | 8.43 Cr | 0.99 Cr |
| Net Income Common Stockholders | 58.56 Cr | 31.45 Cr | 8.43 Cr | 0.99 Cr |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | 58.56 Cr | 31.45 Cr | 8.43 Cr | 0.99 Cr |
| Minority Interests | 0.22 Cr | -1.25 Cr | 0.00 | 0.00 |
| Net Income Including Noncontrolling Interests | 58.34 Cr | 32.71 Cr | 8.43 Cr | 0.99 Cr |
| Net Income Continuous Operations | 58.34 Cr | 32.71 Cr | 8.43 Cr | 0.99 Cr |
| Tax Provision | 12.23 Cr | -7.76 Cr | 4.00 Cr | 0.15 Cr |
| Pretax Income | 70.57 Cr | 24.94 Cr | 12.44 Cr | 1.14 Cr |
| Other Non Operating Income Expenses | 19.26 Cr | 2.82 Cr | 0.22 Cr | — |
| Net Non Operating Interest Income Expense | -21.55 Cr | -9.45 Cr | -2.10 Cr | -0.37 Cr |
| Interest Expense Non Operating | 21.55 Cr | 9.45 Cr | 1.84 Cr | 0.51 Cr |
| Operating Income | 72.86 Cr | 31.55 Cr | 10.89 Cr | 1.25 Cr |
| Operating Expense | 144.69 Cr | 76.83 Cr | 11.67 Cr | 4.79 Cr |
| Other Operating Expenses | 67.48 Cr | 31.35 Cr | 3.47 Cr | 0.34 Cr |
| Depreciation And Amortization In Income Statement | 16.84 Cr | 10.02 Cr | 1.78 Cr | 0.70 Cr |
| Depreciation Income Statement | 16.84 Cr | 10.02 Cr | 0.37 Cr | 0.14 Cr |
| Gross Profit | 217.55 Cr | 108.38 Cr | 22.56 Cr | 6.03 Cr |
| Cost Of Revenue | 180.70 Cr | 106.14 Cr | 12.77 Cr | 8.03 Cr |
| Total Revenue | 398.25 Cr | 214.52 Cr | 35.33 Cr | 14.07 Cr |
| Operating Revenue | 398.25 Cr | 214.52 Cr | 35.33 Cr | 14.07 Cr |
| Total Unusual Items | — | -0.04 Cr | -30000.00 | 0.00 |
| Total Unusual Items Excluding Goodwill | — | -0.04 Cr | -30000.00 | 0.00 |
| Interest Income | — | 0.46 Cr | 0.04 Cr | 0.19 Cr |
| Rent Expense Supplemental | — | 0.90 Cr | 0.14 Cr | 0.01 Cr |
| Net Income Discontinuous Operations | — | 0.00 | 0.00 | 0.00 |
| Special Income Charges | — | -0.04 Cr | -30000.00 | 0.00 |
| Other Special Charges | — | 0.04 Cr | 30000.00 | — |
| Total Other Finance Cost | — | 0.95 Cr | 0.30 Cr | 0.06 Cr |
| Interest Income Non Operating | — | 0.46 Cr | 0.04 Cr | 0.19 Cr |
| Amortization | — | 3.09 Cr | 1.41 Cr | 0.56 Cr |
| Research And Development | — | 40000.00 | 0.00 | 0.00 |
| Selling General And Administration | — | 14.02 Cr | 1.49 Cr | 0.97 Cr |
| Selling And Marketing Expense | — | 4.18 Cr | 0.41 Cr | 0.03 Cr |
| General And Administrative Expense | — | 9.83 Cr | 1.08 Cr | 0.94 Cr |
| Rent And Landing Fees | — | 0.90 Cr | 0.14 Cr | 0.01 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Senores Pharmaceuticals Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.